MoFo Life Sciences

September 23, 2020 - Regulatory, Intellectual Property, Asia
China Patent Linkage Update: Codification and Rulemaking
On July 3, 2020, China’s National People’s Congress published the second draft of the latest amendment to China’s Patent Law (the “Draft Amendment”) for public comments, which were allowed to be submitted by August 16, 2020. The Draft Amendment included proposed revisions to 19
... ›
September 22, 2020 - Licensing + Commercial, United States, FDA, Startup, Data Analytics, Intellectual Property
GSAS Harvard Biotech Club and Morrison & Foerster’s Patent Course Off to a Roaring Start!
By: Michael R. Ward, Matthew Karlyn, Janet Xiao, Matthew A. Chivvis, Jie Zhou, Anna Yuan and Jillian A. Pesin-Fulop
More than 120 life sciences graduate students, post-docs and industry professionals attended the first class of a six part Patent Law Course offered by Morrison & Foerster and the GSAS Harvard Biotech Club on September 16, 2020. The Harvard Biotech Club is a student
... ›
September 09, 2020 - United States, FDA, Biotech, Healthcare, Pharma, Intellectual Property
Pediatric Exclusivity for Biologics
The U.S. Food and Drug Administration’s six-month pediatric exclusivity rules that apply to drugs also largely apply to biologics (albeit with certain distinctions), which may become a valuable life cycle management strategy for biopharmaceutical companies (hereinafter “Sponsors”) in addition to patent exclusionary rights. At
... ›
August 18, 2020 - United States, Litigation, Intellectual Property
Personalized Medicine Claims Get a Boost under New MPEP Revision
By: Meghan McLean Poon
The United States Patent and Trademark Office (USPTO) published the latest revision to its Manual of Patent Examining Procedure (MPEP) on June 30, 2020. According to the Executive Summary, in this revision, nearly all of the 27 chapters have been updated to incorporate new
... ›
August 12, 2020 - United States, Litigation, Pharma, Intellectual Property
Casting a New Light on Diagnostic Patents: “Methods of Preparation” Patent-Eligible
By: Karen G Potter
The ability of life sciences companies to rely on patent protection for diagnostic methods has been eroded over the last ten years, although recent court decisions evidence a rebuilding framework. While courts have consistently invalidated diagnostic methods as lacking patent eligibility, claims re-framed as
... ›
July 25, 2020 - United States, COVID-19, Intellectual Property
Bill Proposes 10 Additional Years for COVID-19 Inventions
By: Desmond P. O'Sullivan
A proposed bill offers a potential boon to patent owners. If passed, the “Facilitating Innovation to Fight Coronavirus Act” will add ten years to the patent term of eligible inventions. However, the bill will temporarily curtail patent owner enforcement rights. Passage is not certain,
... ›
July 13, 2020 - United States, Litigation, Intellectual Property
Should Cos. Use USPTO's New Fast-Track Appeals Program?
By: Anita Choi and Michael R. Ward
Joe Adamczyk, Anita Choi, and Michael Ward authored an article for Law360 covering the U.S. Patent and Trademark Office’s (USPTO) decision to begin accepting petitions for the fast-track appeals pilot program, a new program aimed at shaving off time during ex parte appeal. “Appeals
... ›
June 29, 2020 - United States, COVID-19, Intellectual Property
Expedited Trademark Applications for COVID-19-Related Goods and Services
By: Joyce Liou and Eoin Connolly
Recognizing the need for companies to quickly get products to market that might help combat the COVID-19 pandemic, the United States Patent & Trademark Office is now paving the way for shorter examination timelines for qualifying trademark applications. This could prove especially useful in
... ›
May 21, 2020 - European Union, Intellectual Property
Germany Adopts Administrative Trademark Cancellation Actions
By: Robert Grohmann
On May 1, 2020 the last part of the German Trademark Law Modernization Act ( Markenrechtsmodernisierungsgesetz – “MaMoG”), which contains practical relevant amendments to the procedural rules of the German trademark system, took effect. In particular, an administrative procedure for the revocation and the
... ›
May 14, 2020 - United States, FDA, COVID-19, Intellectual Property
Free Prioritized Examination for COVID-19 Patent Applications
By: Sejin Ahn and Desmond P. O'Sullivan
The United States Patent and Trademark Office (USPTO) announced a Prioritized Examination Pilot Program for COVID-19-related patent applications. To qualify, an applicant must be a small entity or micro-entity and the application must contain at least one claim covering products or process that are
... ›

Topic Archives: Intellectual Property

China Patent Linkage Update: Codification and Rulemaking

GSAS Harvard Biotech Club and Morrison & Foerster’s Patent Course Off to a Roaring Start!

By: Michael R. Ward, Matthew Karlyn, Janet Xiao, Matthew A. Chivvis, Jie Zhou, Anna Yuan and Jillian A. Pesin-Fulop

Pediatric Exclusivity for Biologics

Personalized Medicine Claims Get a Boost under New MPEP Revision

By: Meghan McLean Poon

Casting a New Light on Diagnostic Patents: “Methods of Preparation” Patent-Eligible

By: Karen G Potter

Bill Proposes 10 Additional Years for COVID-19 Inventions

By: Desmond P. O'Sullivan

Should Cos. Use USPTO's New Fast-Track Appeals Program?

By: Anita Choi and Michael R. Ward

Expedited Trademark Applications for COVID-19-Related Goods and Services

By: Joyce Liou and Eoin Connolly

Germany Adopts Administrative Trademark Cancellation Actions

By: Robert Grohmann

Free Prioritized Examination for COVID-19 Patent Applications

By: Sejin Ahn and Desmond P. O'Sullivan